RBC Lifts Eli Lilly Price Target on Expected 'Strong' Q2 Performance of Obesity Drugs

RBC Capital Markets expects Eli Lilly (LLY.SW) to report a "strong" performance from obesity drugs Zepbound and Mounjaro when it publishes its second-quarter results on Aug. 5. The US-based pharmaceutical company's total revenue is forecast to reach $20.74 billion in the quarter, higher than the Visible Alpha consensus of $20.51 billion, according to a Wednesday earnings preview note. Net income is anticipated to come in at $7.86 billion, against the consensus of $7.87 billion. "For 2Q26 we sit ~1% ahead of consensus on sales, driven by +5-6% beats by Zepbound/Mounjaro, with strong US/ex-US volume uptake offsetting expected low-to-mid-teens pricing headwinds. This outweighs lower Verzenio, Taltz, and Trulicity sales. With higher costs we are in line with consensus on 2Q26 earnings," analytsts said. "We anticipate another guidance raise, though not as much as the 1Q26 increase in sales (+2.5% at mid-point) or EPS (+5.8% at mid-point). For the rest of the year we remain positive on Medicare expansion, and ex-US opportunity." As such, the price target was increased to $1,500 from $1,250, with an outperform recommendation on the stock. The research firm also made changes to its.